Bioventus Inc.
NASDAQ:BVSMedical - Devices
+$0.18 today
- Market cap
- $727.20M
- Beta
- 0.67
- P/E (TTM)
- 20.6
- EPS (TTM)
- $0.42
Volume 0.70M
Average 0.56M
BVS Operating Cash Flow
Cash generated by the company's core business operations during the period.
Bioventus Inc.NASDAQ: BVS
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns positive
Q1 FY2026 operating cash flow was $8.93M, compared with -$19.33M a year earlier. Trailing-twelve-month operating cash flow was $102.94M.
Context
- Operating cash flow amounted to 13.0% of revenue in FY2025, up 6.3 pp from a year earlier.
- Operating cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating cash flow holds near $8.93M or moves back toward the trailing-twelve-month quarterly average of $25.73M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 73.98M USD
- Year-over-year change
- +90.7%
- 4-year CAGR
- +33.9%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 73.98M | +90.7% |
| FY2024 | 2024-12-31 | 38.8M | +152.8% |
| FY2023 | 2023-12-31 | 15.34M | +213.3% |
| FY2022 | 2022-12-31 | (13.54M) | -158.9% |
| FY2021 | 2021-12-31 | 22.99M | — |
Operating Cash Flow vs competitors
How BVS compares with its peers on the latest reported figures
- BVS's LTM Mar 2026 operating cash flow of $102.94M is the 2nd largest of the 9 companies compared; the peer median is $32.83M.
- Its year-over-year change of +304.2% is the 2nd highest of 9, against a peer median of +25.0%.
- Operating cash flow amounts to 17.9% of revenue for BVS, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $1.29B | +30.2% | +40.0% | 20.8% | |
| LTM Mar 2026 | $102.94M | +304.2% | — | 17.9% | |
| LTM Mar 2026 | $71.44M | -30.2% | -42.5% | 4.3% | |
| LTM Mar 2026 | $70.58M | +7.7% | — | 18.1% | |
| LTM Mar 2026 | $34.91M | +34.3% | — | 4.2% | |
| LTM Jun 2026 | $31.14M | -8.8% | -11.5% | 39.0% | |
| LTM Mar 2026 | $30.75M | +593.4% | — | 6.0% | |
| LTM Mar 2026 | $9.15M | +288.2% | — | 7.5% | |
| LTM Mar 2026 | $6.47M | +19.9% | +36.4% | 5.6% | |
| Peer median (excluding BVS) | $32.83M | +25.0% | +12.4% | 6.7% | |
Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 11.45M | (144.65M) | (121.2M) | (318K) | 27.27M |
| Depreciation & Amortization | 34.88M | 55.4M | 57.37M | 49.56M | 47.01M |
| Deferred Income Tax | (9.76M) | (46.66M) | (2.38M) | (5.39M) | (909K) |
| Stock-Based Compensation | 19.84M | 17.59M | 2.72M | 10.06M | 12.67M |
| Change in Working Capital | (15.15M) | (29.73M) | (3.18M) | (11.78M) | (13.84M) |
| Accounts Receivables | (20.05M) | (17.67M) | 10.06M | (10.67M) | (916K) |
| Inventory | 3.18M | (18.62M) | (5.99M) | (16.44M) | 8.57M |
| Accounts Payables | 0 | 0 | 0 | 0 | (19.81M) |
| Other Working Capital | 1.72M | 6.56M | (13.24M) | 15.32M | (1.68M) |
| Other Non-Cash Items | (18.28M) | 134.52M | 82.01M | (3.33M) | 1.77M |
| Operating Cash Flow | 22.99M | (13.54M) | 15.34M | 38.8M | 73.98M |
| Capital Expenditures | (20.89M) | (1.48M) | (7.36M) | (1.01M) | (2.56M) |
| Acquisitions (Net) | (262.87M) | 0 | 34.68M | 0 | (686K) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (7.37M) | (114.96M) | (11.51M) | 23.97M | 0 |
| Investing Cash Flow | (283.76M) | (116.44M) | 15.81M | 22.96M | (3.25M) |
| Debt Repayment | 166.2M | 59.62M | (23.26M) | (59.58M) | (42.91M) |
| Common Stock Issued | 109.41M | 5.82M | 778K | 2.44M | 2.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (367K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.88M) | (3.37M) | (4.17M) | 2.56M | (20.61M) |
| Financing Cash Flow | 273.37M | 62.08M | (26.65M) | (54.58M) | (61.44M) |
| Effect of Forex Changes | (228K) | 521K | 629K | (2.56M) | 371K |
| Net Change in Cash | 12.37M | (67.38M) | 5.13M | 4.62M | 9.66M |
| Free Cash Flow | 2.1M | (15.02M) | 7.98M | 37.79M | 71.41M |
Bioventus Inc.
NASDAQ:BVS
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.